Cellectar Biosciences Valuation

Is NV40 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

Below Future Cash Flow Value
Significantly Below Future Cash Flow Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast

Share Price vs Future Cash Flow Value

What is the Fair Price of NV40 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Ultimate guide to DCF valuation for stock investing

Learn how to determine fair value like the best investors in the world.

Below Future Cash Flow Value: Insufficient data to calculate NV40's fair value for valuation analysis.

Significantly Below Future Cash Flow Value: Insufficient data to calculate NV40's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for NV40?

Key metric: As NV40 is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for NV40. This is calculated by dividing NV40's market cap by their current book value.
What is NV40's PB Ratio?
PB Ratio	3x
Book	US$5.56m
Market Cap	US$16.60m

NV40 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	n/a
Enterprise Value/EBITDA	-0.2x
PEG Ratio	n/a

Price to Book Ratio vs Peers

How does NV40's PB Ratio compare to its peers?

The above table shows the PB ratio for NV40 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PB	Estimated Growth	Market Cap
Peer Average	15.9x
HF00 Respiratorius	0.4x	n/a	€13.7m
20B Biomark Diagnostics	61.4x	n/a	€32.8m
8V8 Genetic Analysis	1.2x	n/a	€49.1m
2INV 2invest	0.7x	n/a	€62.9m
NV40 Cellectar Biosciences	3x	23.32%	€16.6m

Price-To-Book vs Peers: NV40 is good value based on its Price-To-Book Ratio (3x) compared to the peer average (7.1x).

Historical Price to Book Ratio

Historical Price to Book Ratio compares a stock's price to the book value of it's equity over time. Higher ratios indicate that investors are willing to pay more for the stock.

Fetching historical data

Price to Book Ratio vs Industry

How does NV40's PB Ratio compare vs other companies in the DE Biotechs Industry?

7 Companies	Price / Book	Estimated Growth	Market Cap
V9Z Aceragen	0.1x	n/a	US$3.12m
V9Z Aceragen	0.1x	n/a	US$2.18m
MDG1 Medigene	0.1x	14.15%	US$2.07m
0C1 Atreca	0.2x	4.34%	US$1.85m

7 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Book vs Industry: NV40 is expensive based on its Price-To-Book Ratio (3x) compared to the European Biotechs industry average (2.9x).

Price to Book Ratio vs Fair Ratio

What is NV40's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

NV40 PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio	3x
Fair PB Ratio	n/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate NV40's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

AnalystPriceTarget

Community Contributor

€2.27

Fair Value

88.9% undervalued

Number of Analysts

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/09/21 02:25
End of Day Share Price	2025/06/24 00:00
Earnings	2025/06/30
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Cellectar Biosciences, Inc. is covered by 7 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Kumaraguru Raja	Brookline Capital Markets
Keith Markey	Griffin Securities
Aydin Huseynov	Ladenburg Thalmann & Company